The Effect of Exercise on Tumor Hypoxia in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy. (SHOR-TEST)

December 12, 2019 updated by: Sissal Sigmundsdóttir Djurhuus, Rigshospitalet, Denmark

The Effect of Exercise on Tumor Hypoxia in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy - a Randomized Controlled Pilot Study

Background and purpose: The purpose of this study is to investigate the effect of one acute exercise bout on tumor hypoxia in patients with localized prostate cancer undergoing radical prostatectomy.

The primary hypothesis is that exercise reduces tumor hypoxia and that the reduction is greater in patients performing one acute high intensity exercise bout compared to no training controls.

The investigators have not been able to identify any prior or current randomized trials investigating exercise and tumor hypoxia, and believe that such research is warranted and would be of great importance. Moreover there is a need for studies including biological measurements to allow a full assessment of the effect of exercise on diverse biomarkers and mechanistic pathways, which may influence cancer survival.

Subjects: Patients with histologically verified prostate adenocarcinoma scheduled for radical prostatectomy at Urologic Department, Rigshospitalet, Copenhagen, Denmark.

Methods: In this randomized controlled pilot study 30 patients with localized prostate cancer undergoing radical prostatectomy will be included and randomized 2:1 to either one single acute High Intensity Interval Training bout or usual care and no training the day prior to radical prostatectomy.

All patients will undergo assessment at inclusion (baseline) and the day prior to surgery.

Assessment includes: anthropometrics; blood pressure; resting hearth rate; hip and waist circumference, ECG, quality of life by self-report questionnaires; fasting blood sample measuring PSA (prostate specific antigen), cholesterol, triglycerides, insulin, c-peptide, HbA1c, glucose and inflammatory markers.

All patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate.

Biological tissue from tumor (primary prostate biopsies) will also be retrieved from the respective local pathological departments and from the perioperative prostate specimen and sent to protocol analyses.

Study Overview

Status

Completed

Conditions

Detailed Description

The purpose of this study is to investigate the effect of one acute exercise bout on tumor hypoxia in patients with localized prostate cancer randomized to one single acute I) High Intensity Interval Training bout compared to (II) usual care and no training prior to radical prostatectomy.

In addition to this the aim is to investigate the effect of one exercise bout on tumor vessel morphology and to investigate the effect of one acute exercise bout on intratumoral immune cell infiltration and to investigate the modulation of tumor-metabolism, -biology and signaling in patients randomized to either one acute High Intensity Interval Training bout compared to usual care and no training, the day prior to surgery.

Moreover this study will explore the acute response in immune cells, hormones and cytokines in blood samples taken before, during and after a single exercise session, and will collect physiological (metabolic profile and metabolic inflammatory markers) and psycho-social (e.g. fatigue, emotional well-being, anxiety) information regarding patients randomized to either one acute High Intensity Interval Training bout compared to usual care and no training, the day prior to surgery.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Copenhagen, Denmark, DK-2100
        • Center for Physical Activity Research, Copenhagen University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Men with histologically verified localized prostate adenocarcinoma undergoing curative intended radical prostatectomy.

Exclusion Criteria:

  • Age: <18 years
  • Any other known malignancy requiring active treatment
  • Performance status > 1
  • Allergy to pimonidazole
  • Ongoing treatment with beta blockers
  • Physical disabilities precluding physical testing and/or exercise
  • Inability to read and understand Danish

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High Intensity Interval Training bout
Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
No Intervention: Controls (usual care)
Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tumor hypoxia
Time Frame: At prostatectomy
Quantification of tumor hypoxia will be assessed using pimonidazole staining
At prostatectomy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intratumoral immune cell infiltration
Time Frame: Primary prostate biopsies and until radical prostatectomy
Intratumoral immune cell infiltration will be quantified using histological analyses
Primary prostate biopsies and until radical prostatectomy
Tumor vessel morphology
Time Frame: Primary prostate biopsies and until radical prostatectomy
Tumor vessel morphology will be evaluated using histological analyses
Primary prostate biopsies and until radical prostatectomy
Tumor metabolism-, biology and signaling
Time Frame: Primary prostate biopsies and until radical prostatectomy
Tumor samples will undergo proteomic analyses in order to uncover potential upregulated biomarkers
Primary prostate biopsies and until radical prostatectomy
Changes in immune cells during an acute exercise bout
Time Frame: From start of exercise bout and until 60 minutes post exercise
Changes in immune cells during an acute exercise bout will be measured in blood samples using flowcytometry
From start of exercise bout and until 60 minutes post exercise
Changes in epinephrine concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
Concentration of epinephrine will be measured in blood samples by radioimmunoassay analyses.
From start of exercise bout and until 60 minutes post exercise
Changes in nor-epinephrine concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
Concentration of nor-epinephrine will be measured in blood samples by radioimmunoassay analyses.
From start of exercise bout and until 60 minutes post exercise
Changes in various interleukines
Time Frame: From start of exercise bout and until 60 minutes post exercise
Concentration of various interleukines will be measured in blood samples by measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
From start of exercise bout and until 60 minutes post exercise
Changes in Tumor Necrosis Factor alpha (TNFa) concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
Concentrations of TNFa will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
From start of exercise bout and until 60 minutes post exercise
Changes in Interferon Gamma (IFNγ) concentration
Time Frame: From start of exercise bout and until 60 minutes post exercise
Concentrations of IFNγ will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses.
From start of exercise bout and until 60 minutes post exercise
Concentration of C-reactive Protein (CRP)
Time Frame: Blood sampling on the day of radical prostatectomy
Concentration of CRP will be measured in fasting blood sample by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Total plasma cholesterol concentration
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of total cholesterol will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Plasma LDL-Cholesterol concentration
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of LDL- cholesterol will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Plasma HDL-Cholesterol concentration
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of HDL- cholesterol will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Plasma triglyceride concentrations
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of triglycerides will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
HbA1C concentration
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of HbA1C will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Plasma Insulin concentration
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of insulin will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Plasma Glucose concentration
Time Frame: Blood sampling on the day of radical prostatectomy
Concentrations of glucose will be measured in fasting blood samples by standard laboratory methods.
Blood sampling on the day of radical prostatectomy
Wattmax-test
Time Frame: At baseline assessment
The participants in the HIIT group will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the maximum watt (wattmax). The test starts with a 3 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. The maximum watt will be calculated.
At baseline assessment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sissal S Djurhuus, MD, PhD student

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

November 24, 2019

Study Completion (Actual)

November 24, 2019

Study Registration Dates

First Submitted

August 24, 2018

First Submitted That Met QC Criteria

September 14, 2018

First Posted (Actual)

September 18, 2018

Study Record Updates

Last Update Posted (Actual)

December 13, 2019

Last Update Submitted That Met QC Criteria

December 12, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on High Intensity Interval Training bout

3
Subscribe